These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 27226207)
1. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use. Lim D; Ngeow J Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207 [TBL] [Abstract][Full Text] [Related]
2. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Cerrato A; Morra F; Celetti A J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198 [TBL] [Abstract][Full Text] [Related]
3. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Liu FW; Tewari KS Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795 [TBL] [Abstract][Full Text] [Related]
4. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics. Rabenau K; Hofstatter E Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114 [TBL] [Abstract][Full Text] [Related]
5. Resurrection of PARP Inhibitors in Breast Cancer. Lyons TG; Robson ME J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424 [TBL] [Abstract][Full Text] [Related]
6. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Lee JM; Ledermann JA; Kohn EC Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061 [TBL] [Abstract][Full Text] [Related]
8. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
9. The development of PARP as a successful target for cancer therapy. Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919 [TBL] [Abstract][Full Text] [Related]
13. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Lupo B; Trusolino L Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313 [TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors: Synthetic lethality in the clinic. Lord CJ; Ashworth A Science; 2017 Mar; 355(6330):1152-1158. PubMed ID: 28302823 [TBL] [Abstract][Full Text] [Related]
20. Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. Shao N; Shi Y; Yu L; Ye R; Shan Z; Zhang Z; Zhang Y; Lin Y Int J Biol Sci; 2019; 15(5):962-972. PubMed ID: 31182917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]